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Dendritic cells and lymphotropic viruses: Who is fooling whom? 
Throughout our early ancestors, our immune system has evolved into a very sophisticated system to 
combat invading pathogens. In turn, pathogenic viruses have evolved and are continuously evolving 
new mechanisms to escape the immune system, increasing their survival in the host and their spread 
throughout the population1,9,19,57.  
This thesis describes the interaction of viruses with a specific type of immune cells: the dendritic cells 
(DCs). DCs are essential for the induction of an antiviral immune response6. However, viruses, 
especially lymphotropic viruses, are thought to subvert DC function for transport from the site of entry 
into the lymphoid tissues57. Furthermore, viruses may target DC function to modulate the immune 
system during established infection, thereby increasing their survival and dissemination to subsequent 
hosts1.   
We have focussed on the first interaction between viruses and DCs at the site of infection. We have 
studied two lymphotropic viruses: human immunodeficiency virus (HIV-1) and measles virus (MV). We 
investigated their interaction with different DC subtypes, including DC-SIGN+ DCs and Langerhans 
cells. While employing virological and immunological assays, we kept asking ourselves: “Are our 
observations beneficial to the host or to the virus?”  
In this general introduction I will briefly introduce the key players, basic concepts, and main questions of 
this thesis. 
 
Dendritic cells have a unique position in the immune system 
The immune system can be divided into the innate and adaptive immune system. Innate mechanisms 
respond fast and provide a first-line of defence against various invading micro-organisms. In contrast, 
adaptive immune responses are relatively slow in onset, pathogen-specific and enable memory to 
prevent illness by a second attack with the same pathogen. The cell type that bridges the innate and 
adaptive immune system is the DC. DCs are present at strategic sites to sense invading pathogens, 
such as the peripheral tissues that line the external environment, including the skin and mucosa (Figure 
1.1). At the site of infection, cells of the innate immune system as well as DCs are activated. The innate 
immune cells perform their immunological function at the site of infection, whereas DCs capture 
pathogens and migrate towards the lymphoid tissues, to induce an adaptive immune response (Figure 
1.1). Thus, DCs operate at the interface of both the innate and adaptive immune system6,28,29,58. 
 
Dendritic cells are professional antigen presenting cells. 
Antigen presenting cells (APCs) internalize antigens for degradation into peptides, which are displayed 
on MHC class molecules to prime naïve T cells. APCs comprise of B cells, macrophages and DCs. DCs 
are the most efficient APCs at activating naïve T cells and are therefore called “the professional 
APCs”6,60.  
DCs were named after their unique cytoplasmic extensions, referred to as dendrites56. DCs are derived 
from haematopoietic precursor cells54 and migrate from the bone marrow via the blood to seed in 
different sites of the body, where the cells they have an immature state. Immature DCs are 
characterized by a high endocytic capacity, which enables them to sample the surrounding environment 
for invading pathogens or environmental triggers. Upon antigen encounter, DCs acquire a mature 
phenotype: their dendritic processes are prolonged; they up-regulate cell-surface receptors that act as 
co-stimulatory molecules in T cell activation such as CD80, CD83 and CD86, and the increase CCR7 
expression, a chemotactic receptor that mediates DC migration into the lymphoid tissues37,55,59. In the 
meantime, DCs process the internalized antigen into peptides, which are presented in the context of 
major histocompatibility complex (MHC) class molecules43,61. To prime antigen specific CD4+ T cells two 
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signals are required: the specific interaction of the MCH class-II:peptide complex with the T cell receptor 
and a co-stimulatory signal provided by the maturation markers on DCs50. In addition to MHC class-II 
presentation, it is now evident that DCs present peptides derived from internalized antigen in the 
context of MHC class-I, a process referred to as cross-presentation4,25,61.  
 
 
Figure 1.1 Dendritic cells induce an adaptive immune response.  
Immature DCs are present at strategic sites in the body to sense invading pathogens. Upon capture of pathogens, DCs 
mature and migrate towards the lymphoid tissues. In the meanwhile, DCs degrade the pathogen and present peptides 
derived from the pathogen into the context of MHC molecules to T cells. Pathogen-specific T cells will be activated and 
mediate an adaptive immune response. 
 
Dendritic cells skew effector T cells into different directions 
Specific immune responses are required to clear infections with diverse classes of pathogens, and this 
is mediated by different types of effector T cells. DCs, but also other cells of the innate immune system, 
produce cytokines and express surface molecules specific for the class of pathogen they have 
encountered, which participate in the skewing of CD4+ T cells into different sorts of effector T helper 
cells. At this moment three effector T subpopulations have been described: T helper-1, -2 and -17 cells 
(Th-1, Th-2, Th-17)26,29,30,64. These different effector T cells provide assistance to other cells of the 
adaptive or innate immune system to adequately respond to the pathogen. For acute viral infections a 
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Th-1 response is essential, since this augments the activation of a cellular immune response, including 
proliferation of viral specific CTLs17,30.  
 
Pattern-recognition receptors on dendritic cells 
DCs express different classes of pathogen receptors, including pattern recognition receptors 
(PRRs)22,24,29. PRRs recognize small molecular motifs that can be found on pathogens. Two main 
families of PRRs are the Toll-like receptors (TLRs) and the C-type lectins10,23,42. TLRs recognize a 
variety of pathogenic structures, including viral RNAs. TLR signaling results in DC maturation as well as 
cytokine production27,33,36. C-type lectins recognize carbohydrate structures on pathogens16, facilitating 
pathogen capture and internalization22,23. This receptor family is not only important in antigen 
presentation, but might adjust the immune response by cross-talk with TLRs20,62. 
 
Viruses 
Although very small, and often comprised of only a few different proteins, viruses are masters of 
manipulating their host for replication, survival and spread17. A virus is unable to grow or replicate 
autonomously, and therefore uses the machinery and metabolism of a host cell to replicate. Viruses use 
specific receptors to mediate attachment and fusion of the viral- and cell membrane. This specificity 
largely determines the viral host range (e.g. human, bird) and within the host, viral tropism (host cell of 
the virus e.g. T cell, epithelial cell). Here we have focussed on lymphotropic viruses that have a specific 
tropism for lymphocytes, but might also infect macrophages, dendritic cells and other leukocytes17. 
 
Viral transmission 
To initiate infection, a virus needs to approach and attach to the body surfaces of a novel host. 
Subsequently, the virus must reach its target organs, infect its host cells and start the replication cycle. 
All of these processes have to occur, while encountering the host defense mechanisms, such as the 
surface barriers, the innate immune system and the starting adaptive immune response. Transmission 
of viruses from an infected host to a susceptible individual occurs in different ways, such as via 
aerosols, by sexual contact, faecal-oral contamination, and direct inoculation via infected needles or an 
insect bite. The tropism and transmission route of a virus dictates the mechanisms a virus employs to 
colonize the host17. 
For example, a rhinovirus, the causative agent of the common cold enters the body via the upper 
respiratory tract. Here, the surface barriers destroy a part of the virus. However a small population of the 
virus survives and reaches the surface of the epithelial cells. The virus binds to its entry receptor, enters 
the cell and replication is started7. For this virus, the processes of entry, primary replication, and tissue 
tropism all occur at the same anatomic localization (Figure 1.2)7,17.  
Other viruses, however, enter the body at one site and, in order to produce disease, spread to a distant 
area. For these viruses, classical textbooks3,17 distinguish between primary viral replication near the 
entry site of infection and secondary replication at the target organ for infection. However, viruses that 
are unable to infect cells at the site of entry (e.g. HIV-1) are thought to use other mechanisms to reach 
their target cells.  
In vitro and ex vivo studies have suggested a prominent role for DCs in the transmission of lymphotropic 
viruses48,57,65. To elicit their function in the immune system, DCs mediate transport of antigens from the 
periphery towards the lymphoid tissue, thereby bridging the site of entry of the lymphotropic virus with 
their site of replication. Viruses are therefore thought to hijack DC function to gain access into regions 
rich of viral host cells. This mechanism allows these viruses to bypass the normally impermeable 
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mucosal barrier where their target cells are scarce and the innate immune response might destroy them 
(Figure 1.2). 
 
 
Figure 1.2 Different routes of viral transmission. Viruses with a tropism for cells at the site of entry can directly infect the 
host cells upon transmission (left side) and might spread to other tissues after a first round of replication (middle). 
Lymphotropic viruses without a tropism for cells at the site of entry, might exploit DCs in the peripheral tissues to migrate 
to their host cells in the lymphoid tissues (right side). 
  
Anti-viral immune response in acute infections  
Human body surfaces are equipped with mechanical and chemical barriers to stop invading pathogens. 
These mechanical barriers include impermeable tight junctions between the epithelial/epidermal cells, 
the thick and dry keratin layer of the skin, the mucus which traps viruses, and actions, such as sneezing 
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and flushing to abandon approaching viruses. Chemical barriers consist of the low pH of the body fluids 
and antimicrobial products (defensins, lysozyme, pepsin) that are secreted at the body surfaces8,29,34,44.  
After viral entry into the host, the innate immune system is activated by the interaction of viruses with 
different PRRs31,32,47, resulting in inflamation and the influx of innate immune cells. Viral-infected cells 
induce the production of specific interferons (type-I IFNs)2,52. IFNs have multiple antiviral actions, 
including apoptosis of viral infected cells, inhibition of viral replication, increased expression of MHC 
class-I molecules, and the induction of killing of virus-infected cells by NK cells.  Moreover, the 
complement system is activated, resulting in increased phagocytosis of viruses2,29. 
After a couple of days, the adaptive immune system is primed by APCs. A cellular response is induced, 
including the activation of cytotoxic T-lymphocytes (CTLs), that specifically kill viral-infected cells and 
which are essential for clearing a primary viral infection17. Moreover, memory B and T lymphocytes are 
induced to prevent re-infection29.  
 
Subsets of dendritic cells and their role during viral infections 
DCs are a heterogeneous population of cells, which consist of different subsets, based on the 
expression of markers and functional capacities63. Roughly, DCs can be divided into myeloid DCs and 
plasmacytoid DCs (pDCs)12,13,49. PDCs are primarily located in blood and lymphoid organs, but they are 
also found at sites of inflammation12. pDCs have an important role in the innate antiviral immune 
response by producing high amounts of IFNs upon activation12,40 (Figure 1.3).  Myeloid DCs are efficient 
antigen presenting cells and can induce antiviral Th-1 responses by the production of cytokines, such 
as IL-12 (Figure 1.3). Myeloid DCs can be subdivided into different subtypes54. At the sites of viral entry, 
such as skin and the stratified epithelial tissues, two myeloid DC subsets are present with a specific 
localization: namely Langerhans cells (LCs) in the epithelia and epidermis and DC-SIGN+ DCs in the 
subepithelia and dermis. In most healthy tissues, a virus will therefore first encounter LCs followed by 
the DC-SIGN+ DCs, and while further infiltrating in the body it will approach other myeloid DC subsets 
and pDCs. However, this localisation is distinct in other tissues, such as the columnar epithelium. 
 
Viral subversion of DC function 
Within the host a constant battle exists between the host’s immune system and invading pathogens. 
Pathogens have developed a variety of immune evasive strategies to enable survival and replication in 
the host, leading to chronic or lethal infections. Viruses in general, but some in particular, evolve 
extremely fast, resulting in a continuous flow of mutants that pressure immunity and possibly escape 
immune surveillance. The last decades a variety of viral escape mechanisms has been unravelled, 
including inhibition of innate as well as adaptive immune responses19. 
Since DCs have a crucial function in the initiation and shaping of adaptive immune responses, viral 
escape mechanisms are thought to include subversion of DC function (reviewed in1). A few examples: 
The number and function of plasmacytoid and myeloid blood DCs is decreased in HIV-1-infected 
individuals14,15,18; herpes viruses actively inhibit antigen presentation and co-stimulation by DCs35; 
measles virus interferes with the activation of T cells by DCs51,53; lymphotropic viruses target DCs for 
transmission from the site of entry to the lymphoid tissues21. Thus, viruses continuously evolve 
strategies to subvert DC function; however, most of the underlying mechanisms still remain to be 
elucidated. A better understanding will lead to more insight into our immune system and viral pathology. 
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Studying viral transmission to stop viral epidemics 
To slow down or cure a viral epidemic, infections need to be cleared or prevented. Since viruses are 
small, use the host cell machinery to replicate, and rapidly mutate, targets for antiviral drugs are scarce 
and are quickly evaded by the virus. The last decades several effective antiviral drugs have been 
developed. Nevertheless most viral infections still lack a curative treatment.  
The best way to restrict an epidemic is to prevent new infections. Moreover, prevention is the only 
method to impede viral epidemics without a curative treatment. Vaccination has been the most 
successful viral prevention method, resulting in the eradication of smallpox, and a strong reduction of 
the incidence of polio, measles and rubella3. However, vaccines are not available for every virus, 
especially not for viruses that are rapidly mutating, such as HIV-139,41,46. Therefore genital creams or 
gels containing antiviral compounds (‘microbicides’) are being developed, aiming to prevent HIV-1 
transmission5,38,45.  
The first results have indicated that different viruses use similar molecular mechanisms to infect a host. 
Hypothetically, interference with these mechanisms might provide a solution to stop a pandemic caused 
by an unknown virus. Moreover, unravelling these mechanisms will provide insights in how our immune 
system interacts with viruses, which could result in better vaccination strategies38. 
 
 
Thesis outline 
In this thesis I will describe our investigations on viral transmission with a focus on two lymphotropic 
viruses: HIV-1 and MV. HIV-1 and MV are very different in some aspects, but also share similarities 
(Table 1). 
 
Table 1. Similarities and differences between measles virus (MV) and human immunodeficiency virus 
(HIV-1) 3 
 
 MV HIV-1 
Family Paramyxoviridea Retroviridae 
Site of entry Respiratory tract Genital tract or parental 
Entry receptor CD150 CD4 + CCR5/CXCR4 
Main target cells B cells, T cells T cells, macrophages 
Infectivity High Low 
Immune response Efficient, clears infection Not efficient, chronic infection 
Immune suppression Severe, but transient Severe and chronic 
Treatment No Antiviral drugs 
Vaccine Yes No 
 
 
Already in 1992, Cameron et al. described that DCs efficiently transmit HIV-1 to T cells11. A large 
number of studies have further investigated the interaction between HIV-1 and DCs. However, the 
receptors involved in this process have been strongly debated. In Section 2 we will discuss the current 
knowledge on the interaction between HIV-1 and an important DC subset, the DC-SIGN+ DCs. We will 
show new data on the internalisation of HIV-1 in DC-SIGN+ DCs, visualized using electron-microscopy 
and demonstrate that DCs also express another novel HIV-1 attachment receptor on DCs, which is 
called syndecan-3.  
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Several studies have demonstrated that DC-SIGN+ DCs are involved in transmission of various 
lymphotropic viruses. We have investigated the interaction between DCs and MV and this is described 
in Section 3. We have examined the in vivo role of DCs in MV infection by infecting macaques with a 
recombinant MV expressing EGFP, revealing important roles for both DCs and lymphocytes in MV 
pathogenesis. The function of DCs was further explored by investigating the receptors for MV on human 
DC-SIGN+ DCs. DC-SIGN was shown to be a receptor for MV and the role for MV infection, 
transmission and antigen presentation was further investigated. 
 
Figure 1.3 The role of dendritic cells during acute viral infection.  
Myeloid DCs are present in the peripheral tissues where viruses enter the body. They capture the viruses and mediate antigen 
presentation to T cells. By production of specific cytokines they shift the immune system towards a cellular immune response. 
Upon encounter of viruses, plasmacytoid DCs start to produce interferons. The cellular immune response and the interferons 
slow down viral replication and mediate killing of infected cells. 
 
In Section 4, we have addressed the specificity of DC-SIGN for viral ligands. The interaction of DC-
SIGN with herpes simplex virus and human papilloma virus like particles was examined. The role of DC-
SIGN in our immune system will be further discussed.  
In Section 5, we have investigated the role of different DC subsets at the site of viral entry. We have 
observed that LCs are not efficiently infected with HIV-1 compared to DC-SIGN+ DCs. The C-type lectin 
Langerin efficiently captures virus for degradation, leading to protection of LCs and other target cells 
against HIV-1 infection. These results suggested that LCs fulfil an innate antiviral barrier function, 
protecting the host against invading viruses. We have therefore determined whether this protective 
function is specific for HIV-1 or whether it applies to more viruses, such as MV. Furthermore, we have 
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investigated whether capture of viruses by Langerin results in antigen presentation in the context of 
MHC-class-II and cross-presentation in the context of MHC-class-I.  
In Section 6, we will describe how risk factors contribute to HIV-1 transmission. The presence, density 
and phenotype of LCs have been characterized in different genital tissues. Furthermore, we have 
investigated how LCs respond to co-infection with either herpes simplex virus, bacterial or fungal 
pathogens, and how this altered LC phenotype affects the susceptibility to HIV-1 transmission.  
In Section 7 we will elaborate on the implications of the previous sections for the prevention of HIV-1 
transmission. We have investigated the impact of candidate antiviral compound C5A on viral 
transmission. In the final Section 8, we will answer the question “Dendritic cells and lymphotropic 
viruses: Who is fooling whom?” We will discuss our data on a molecular, viral, cellular, host and global 
level. Data in this thesis and experimental/epidemiological data of others indicate that HIV-1 
transmission should not be considered as a static but a fluid process, depending on the exposed tissue, 
viral loads of the infected partner, environmental and host factors. We will propose a ´multi-layered´ 
model to describe HIV-1 transmission, to discuss what research is needed to understand viral 
transmission and to ultimately stop transmission of severe viral pandemics. 
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